Gerry Oster
YOU?
Author Swipe
Adult immunization against hepatitis B: Does the number of jabs matter? Open
Use of a two-dose HBV vaccine would increase the number of adults fully seroprotected at one year compared with the number expected with a three-dose vaccine. Notwithstanding its higher unit cost, mean expected cost per person seroprotecte…
Clinical staging in amyotrophic lateral sclerosis: analysis of Edaravone Study 19 Open
Objective This was a post hoc analysis of the Edaravone Phase III Study MCI186-19 (‘Study 19’) to examine the utility of clinical staging systems as end points in clinical trials in amyotrophic lateral sclerosis (ALS). Methods Amyotrophic …
View article: Cover Image, Volume 22, Issue 11
Cover Image, Volume 22, Issue 11 Open
The outside back cover image is based on the Original Article A pragmatic randomized clinical trial of insulin glargine 300 U/mL versus first-generation basal insulin analogues in insulin-naïve adults with type 2 diabetes: 6-month outcomes…
Pharmacotherapy patterns in patients with chronic idiopathic constipation beginning treatment with linaclotide or lubiprostone in the United States Open
Most patients with CIC receive linaclotide or lubiprostone for 1 year. Additional research is warranted to understand the potential reason(s) for early discontinuation.
View article: A pragmatic randomized clinical trial of insulin glargine 300 U/ <scp>mL</scp> vs first‐generation basal insulin analogues in insulin‐naïve adults with type 2 diabetes: 6‐month outcomes of the <scp>ACHIEVE</scp> Control study
A pragmatic randomized clinical trial of insulin glargine 300 U/ <span>mL</span> vs first‐generation basal insulin analogues in insulin‐naïve adults with type 2 diabetes: 6‐month outcomes of the <span>ACHIEVE</span> Control study Open
Aims To compare the safety and efficacy of insulin glargine 300 U/mL (Gla‐300) versus first‐generation standard‐of‐care basal insulin analogues (SOC‐BI; insulin glargine 100 U/mL or insulin detemir) at 6 months. Methods In the 12‐month, op…
View article: P522 Prior pharmacotherapy patterns among patients with IBD in the USA initiating biologic therapy
P522 Prior pharmacotherapy patterns among patients with IBD in the USA initiating biologic therapy Open
Background Treatment for inflammatory bowel disease (IBD: Crohn’s disease [CD] and ulcerative colitis [UC]) has shifted from symptom management using corticosteroids to targeted therapies such as tumour necrosis factor (TNF) inhibitors. An…
Risk and Economic Burden of Peristomal Skin Complications Following Ostomy Surgery Open
PURPOSE: The purpose of this study was to examine the incidence and economic burden of peristomal skin complications (PSCs) following ostomy surgery. DESIGN: Retrospective cohort study based on electronic health records and administrative …
Relationship of American Spinal Injury Association Impairment Scale Grade to Post-injury Hospitalization and Costs in Thoracic Spinal Cord Injury Open
BACKGROUND The lifetime economic burden of thoracic spinal cord injury (SCI) is known to be high, but evidence of variability of costs in relation to the American Spinal Injury Association Impairment Scale (AIS) grade is limited. OBJECTIVE…
Predictors of near-term fracture in osteoporotic women aged ≥65 years, based on data from the study of osteoporotic fractures Open
Several clinical characteristics predictive of hip and non-vertebral fracture within a 1-year follow-up period among elderly women with osteoporosis were identified, and a subset of those for hip fracture was incorporated into a risk asses…
View article: Clinical and Economic Burden of Peristomal Skin Complications in Patients With Recent Ostomies
Clinical and Economic Burden of Peristomal Skin Complications in Patients With Recent Ostomies Open
Approximately one-third of ostomy patients over a 5-year study period had evidence of PSCs within 90 days of surgery. Costs of care were substantially higher for patients with these complications.
View article: Achieve control: a pragmatic clinical trial of insulin glargine 300 U/mL versus other basal insulins in insulin-naïve patients with type 2 diabetes
Achieve control: a pragmatic clinical trial of insulin glargine 300 U/mL versus other basal insulins in insulin-naïve patients with type 2 diabetes Open
www.clinicaltrials.gov identifier is NCT02451137.
Oral 5-Aminosalicylate, Mesalamine Suppository, and Mesalamine Enema as Initial Therapy for Ulcerative Proctitis in Clinical Practice with Quality of Care Implications Open
Background. Ulcerative proctitis (UP) is typically treated initially with oral 5-aminosalicylate (“5-ASA”), mesalamine suppository, or mesalamine enema (“UP Rx”). Little is known about their effectiveness in practice. Methods. Using a US h…